These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10577972)

  • 1. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction.
    van den Berg WB; Joosten LA; Kollias G; van De Loo FA
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I40-8. PubMed ID: 10577972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha and IL-1 beta are separate targets in chronic arthritis.
    van den Berg WB; Joosten LA; van de Loo FA
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S105-14. PubMed ID: 10589368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint inflammation and cartilage destruction may occur uncoupled.
    van den Berg WB
    Springer Semin Immunopathol; 1998; 20(1-2):149-64. PubMed ID: 9836374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone.
    Lubberts E; Joosten LA; Helsen MM; van den Berg WB
    Cytokine; 1998 May; 10(5):361-9. PubMed ID: 9619374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17.
    Joosten LA; Abdollahi-Roodsaz S; Heuvelmans-Jacobs M; Helsen MM; van den Bersselaar LA; Oppers-Walgreen B; Koenders MI; van den Berg WB
    Arthritis Rheum; 2008 Jan; 58(1):98-108. PubMed ID: 18163514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis.
    Kuiper S; Joosten LA; Bendele AM; Edwards CK; Arntz OJ; Helsen MM; Van de Loo FA; Van den Berg WB
    Cytokine; 1998 Sep; 10(9):690-702. PubMed ID: 9770330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies.
    Lewthwaite J; Blake S; Hardingham T; Foulkes R; Stephens S; Chaplin L; Emtage S; Catterall C; Short S; Nesbitt A
    Ann Rheum Dis; 1995 May; 54(5):366-74. PubMed ID: 7794042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I.
    van den Berg WB; Bresnihan B
    Baillieres Best Pract Res Clin Rheumatol; 1999 Dec; 13(4):577-97. PubMed ID: 10652641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arguments for interleukin 1 as a target in chronic arthritis.
    van den Berg WB
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i81-4. PubMed ID: 11053095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production.
    Abdollahi-Roodsaz S; Joosten LA; Helsen MM; Walgreen B; van Lent PL; van den Bersselaar LA; Koenders MI; van den Berg WB
    Arthritis Rheum; 2008 Dec; 58(12):3753-64. PubMed ID: 19035506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis.
    Koenders MI; Marijnissen RJ; Devesa I; Lubberts E; Joosten LA; Roth J; van Lent PL; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2011 Aug; 63(8):2329-39. PubMed ID: 21520013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
    Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
    J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
    Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
    Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts.
    O' Gradaigh D; Ireland D; Bord S; Compston JE
    Ann Rheum Dis; 2004 Apr; 63(4):354-9. PubMed ID: 15020327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis.
    Mullazehi M; Mathsson L; Lampa J; Rönnelid J
    Arthritis Rheum; 2006 Jun; 54(6):1759-71. PubMed ID: 16736518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.
    Koenders MI; Joosten LA; van den Berg WB
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii29-33. PubMed ID: 17038468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE; Tetlow LC
    Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons for joint destruction from animal models.
    van den Berg WB
    Curr Opin Rheumatol; 1997 May; 9(3):221-8. PubMed ID: 9204257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.